BioVeda China Fund
24
35M
21
1.26
6
0.12
4
- Stages of investment
- Areas of investment
Summary
BioVeda China Fund appeared to be the VC, which was created in 2005. The venture was found in Asia in China. The main department of described VC is located in the Shanghai.
The fund has no exact preference in some founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ASLAN Pharmaceuticals, DiaCarta, CARsgen Therapeutics. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.
This organization was formed by ZHI YANG. Besides them, we counted 5 critical employees of this fund in our database.
The top activity for fund was in 2014. This BioVeda China Fund works on 1 percentage points more the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 50 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 50 - 100 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the BioVeda China Fund, startups are often financed by Morningside Group, BioVeda Capital, Sanofi. The meaningful sponsors for the fund in investment in the same round are SDIC Venture Capital, New Horizon Capital, Morningside Group. In the next rounds fund is usually obtained by KTB Ventures, Jolly Innovation Ventures, 3E Bioventures.
Investments analytics
Analytics
- Total investments
- 24
- Lead investments
- 6
- Exits
- 4
- Rounds per year
- 1.26
- Follow on index
- 0.12
- Investments by industry
- Biotechnology (16)
- Pharmaceutical (11)
- Health Care (10)
- Medical (6)
- Health Diagnostics (4) Show 23 more
- Investments by region
-
- Germany (1)
- China (15)
- United States (6)
- Iceland (1)
- Singapore (1)
- Peak activity year
- 2014
- Number of Unicorns
- 2
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 254M
- Group Appearance index
- 0.50
- Avg. company exit year
- 10
- Avg. multiplicator
- 3.96
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Boan Biotech | 05 Jan 2021 | Biotechnology, Pharmaceutical, Therapeutics, Product Research | Early Stage Venture | 105M | Liaoning, Yantai, China |
| CaptainPicks | 01 Aug 2021 | Software | Seed | ||
| DiaCarta | 09 Jan 2015 | Biotechnology, Genetics, Medical | Early Stage Venture | 8M | United States, California, Hayward |
| Epycure | 01 Jul 2019 | E-Commerce, Internet, Direct Sales, Wellness, Dietary Supplements | Seed | 352K | Ile-de-France, Paris, France |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.